Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 31;20(1):2351675.
doi: 10.1080/21645515.2024.2351675. Epub 2024 Jun 4.

The economic rationale for cell-based influenza vaccines in children and adults: A review of cost-effectiveness analyses

David Fisman  1 , Norberto Giglio  2 , Myron J Levin  3 , Van Hung Nguyen  4 , Stephen I Pelton  5 , Maarten Postma  6   7   8   9 , Jesús Ruiz-Aragón  10 , Analia Urueña  11 , Joaquin F Mould-Quevedo  12
Affiliations
Review

The economic rationale for cell-based influenza vaccines in children and adults: A review of cost-effectiveness analyses

David Fisman et al. Hum Vaccin Immunother. .

Abstract

Seasonal influenza significantly affects both health and economic costs in children and adults. This narrative review summarizes published cost-effectiveness analyses (CEAs) of cell-based influenza vaccines in children and adults <65 years of age, critically assesses the assumptions and approaches used in these analyses, and considers the role of cell-based influenza vaccines for children and adults. CEAs from multiple countries demonstrated the cost-effectiveness of cell-based quadrivalent influenza vaccines (QIVc) compared with egg-based trivalent/quadrivalent influenza vaccines (TIVe/QIVe). CEA findings were consistent across models relying on different relative vaccine effectiveness (rVE) estimate inputs, with the rVE of QIVc versus QIVe ranging from 8.1% to 36.2% in favor of QIVc. Across multiple scenarios and types of analyses, QIVc was consistently cost-effective compared with QIVe, including in children and adults across different regions of the world.

Keywords: Influenza; cell-based influenza vaccine; cost-effectiveness analysis.

PubMed Disclaimer

Conflict of interest statement

D.F. has received honoraria for participating in advisory boards with Merck, Sanofi-Pasteur, CSL Seqirus, Pfizer, and AstraZeneca related to influenza, SARS-CoV-2, and pneumococcal vaccines.

N. G. received funding for investigator-led studies from GSK, MSD, CSL Seqirus, Takeda, and Sanofi-Pasteur and Global Vaccine Data Network. N.G. has received honoraria from CSL Seqirus, Takeda, and Pfizer for acting as a speaker in congresses, and from GSK, Takeda, and CSL Seqirus for taking part in advisory boards.

M.J.L. received honoraria from CSL Seqirus, GSK, Pfizer, Moderna, Curevo, AstraZeneca, and Dynavax for taking part in advisory boards. M.J.L. has received institution funding for investigator-led studies from GSK.

V.H.N. received funding for conducting RWE and CEAs on vaccines from Takeda, CSL Seqirus, Pfizer, and Moderna. V.H.N. has also received honoraria from those companies for taking part in advisory boards.

S.I.P. has received honoraria from CSL Seqirus as a consultant on research design and analysis and participation in advisory boards on influenza vaccines.

M.P. has received honoraria from CSL Seqirus for taking part in advisory boards.

J.R.A. has received honoraria from CSL Seqirus, GSK, and MSD for taking part in advisory boards.

A.U. received institution funding for investigator-led studies from GSK, MSD, CSL Seqirus, Takeda, and Sanofi-Pasteur. A.U. has also received honoraria from CSL Seqirus and Takeda for acting as a speaker in congresses, and from GSK, Takeda, Sanofi, and CSL Seqirus for taking part in advisory boards. She is a member of the Directory board of Sociedad Argentina de Vacunología y Epidemiologia (SAVE).

J.M.Q. is an employee of CSL Seqirus.

Figures

Figure 1.
Figure 1.
CE of QIVc vs QIVe, itemized by study perspective, time horizon, population and estimated local willingness-to-pay threshold.,,
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. de Courville C, Cadarette SM, Wissinger E, Alvarez FP.. The economic burden of influenza among adults aged 18 to 64: a systematic literature review. Influenza Other Respir Viruses. 2022;16(3):376–12. doi:10.1111/irv.12963. - DOI - PMC - PubMed
    1. Villani L, D’Ambrosio F, Ricciardi R, de Waure C, Calabrò GE. Seasonal influenza in children: costs for the health system and society in Europe. Influenza Other Respir Viruses. 2022;16(5):820–31. doi:10.1111/irv.12991. - DOI - PMC - PubMed
    1. World Health Organization . Influenza. https://www.who.int/teams/health-product-policy-and-standards/standards-....
    1. Paget WJ, Balderston C, Casas I, Donker G, Edelman L, Fleming D, Larrauri A, Meijer A, Puzelli S, Rizzo C, et al., EPIA collaborators . Assessing the burden of paediatric influenza in Europe: the European Paediatric Influenza Analysis (EPIA) project. Eur J Pediatr. 2010;169(8):997–1008. doi:10.1007/s00431-010-1164-0. - DOI - PMC - PubMed
    1. Ruf BR, Knuf M. The burden of seasonal and pandemic influenza in infants and children. Eur J Pediatr. 2014;173(3):265–76. (In eng). doi:10.1007/s00431-013-2023-6. - DOI - PMC - PubMed

Publication types

Substances